Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

escalating doses of TB-402. It is anticipated that the study will conclude by the end of 2010.

Patrik De Haes, CEO of ThromboGenics, commented on today's news "We are very excited about the start of the Phase II trial for TB-402. Our work to date suggests that this novel agent could represent a major advance in anti-coagulant therapy, given our expectation that it will cause fewer unwanted bleeding events and will require no monitoring of patients. This combined with its ability to be used as a "one-off" treatment could make TB-402 the anti-coagulant of choice to prevent DVT in patients undergoing surgery. Given the size of the market opportunity for TB-402 and the sales reach that will be needed to engage with the potential prescribers of TB-402, it is our intention to seek a partner to undertake the later stage development and commercialisation of this exciting new agent."

Svein Mathisen, CEO of BioInvent, also commented, "The initiation of this Phase II trial is another successful step forward in the clinical development of our antibody product development portfolio. TB-402 addresses a broad market and has potentially significant advantages over existing anti-coagulants. We are hopeful it will have application in a number of clinical settings."

About Deep Vein Thrombosis (DVT)

DVT is caused when a blood clot forms in a deep vein, most commonly in the deep veins of the lower leg. DVT is a major public health issue and it is estimated that in the U.S. alone, more than 350,000 individuals are affected by DVT or pulmonary embolism (PE) each year. Moreover, DVT and PE together may be responsible for more than 100,000 deaths in the U.S. each year.(1)

It is estimated that by 2015, 1.4 million patients will undergo knee replacement and 600,000 patients will undergo hip replacement in the U.S. if current trends persist.(2) Patients undergoing hip replacement or knee surgery are p
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... July 24, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... Potassium Sulphate basic information, including its definition, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:7/24/2014)... , July 24, 2014 WIRB-Copernicus ... of regulatory and ethical review services for clinical ... Biosciences. Formerly a division of Richmond, ... the leading biosafety and biosecurity consulting firm in ... this addition, WCG,s biosafety division – WCG Biosafety™ ...
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... SHANGHAI, Aug. 10 /PRNewswire-Asia-FirstCall/ ... ("China-Biotics," "the Company"), a leading Chinese firm,specializing ... of probiotics products, today announced that the ... has been,awarded the High-Technology Enterprise Certificate (the ...
... /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... Patent and Trademark Office (PTO) has issued United ... Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method ... to treat certain cancers. The patent, licensed from ...
... ... launched its revolutionary Trusted LASIK Surgeons directory service and website at ... improve their vision and find a highly qualified eye surgeon who can ... directory apart is a unique screening process ensuring that only those who ...
Cached Biology Technology:China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 2China-Biotics, Inc. Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate 3OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 2OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011 3Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 2Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 3Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 4Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 5Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 6Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 7Trusted LASIK Surgeons Welcomes Fort Lauderdale Vision Correction Surgery Expert Raymond P. Gailitis, M.D., F.A.C.S. 8
(Date:7/25/2014)... girls reach puberty is influenced by ,imprinted genes,a subset of ... gene. This is the first evidence that imprinted genes ... of this study were published today in the journal ... menarche, is a marker for the timing of puberty in ... varies between girls, is an inherited trait, and is linked ...
(Date:7/25/2014)... of a molecular testing panel developed at UPMC ... initial surgery for patients with thyroid nodules and ... Cancer Institute (UPCI), partner with UPMC CancerCenter., The ... and other diagnostic testing agencies, improved the chances ... 30 percent, according to the study published this ...
(Date:7/25/2014)... CORAL SPRINGS, Florida , July 25, 2014 /PRNewswire/ ... influential as more consumers are turning to digital technology ... NXT-ID, Inc. (OTCBB: NXTD), Google Inc. (NASDAQ: ... Visa Inc. (NYSE: V ), Apple Inc. ... FTNT) NXT-ID, Inc., (OTCQB: NXTD) a biometric ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... Down syndrome (DS) is the most common genetic disorder ... a chromosomal abnormality. It occurs as a result of ... usual two. It causes substantial physical and behavioral abnormalities, ... to severe but which further deteriorates as individuals with ...
... Tropical Research Institute and University of Costa Rica asked ... webs. Repeating old, widely quoted but poorly documented studies ... legs are protected by a covering of branching hairs ... published online in the journal, Naturwissenschaften . , ...
... in size over time, they haven,t necessarily grown in ... according to a recently published study appearing in the ... scientists from the USDA Forest Service and the University ... of wildfires on four national forestsKlamath, Mendocino, Shasta-Trinity and ...
Cached Biology News:Understanding and treating the cognitive dysfunction of Down syndrome and Alzheimer's disease 2Study of wildfire trends in Northwestern California shows no increase in severity over time 2
4',6-Diamidino-2-phenylindole dihydrochloride...
...
Used in May-Grunwald Giemsa stain....
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
Biology Products: